2020
DOI: 10.1016/j.jaad.2020.04.044
|View full text |Cite
|
Sign up to set email alerts
|

Varicella-like exanthem as a specific COVID-19–associated skin manifestation: Multicenter case series of 22 patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

14
368
5
48

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 335 publications
(435 citation statements)
references
References 5 publications
(1 reference statement)
14
368
5
48
Order By: Relevance
“…Direct immunofluorescence was negative, including antibody–fluorophore conjugates to IgG, IgM, IgA, complement proteins C1q, C3, and C4c, and fibrinogen. This histology is similar to that previously reported 5 …”
Section: Figuresupporting
confidence: 92%
“…Direct immunofluorescence was negative, including antibody–fluorophore conjugates to IgG, IgM, IgA, complement proteins C1q, C3, and C4c, and fibrinogen. This histology is similar to that previously reported 5 …”
Section: Figuresupporting
confidence: 92%
“…Recalcati et al, 8 who conducted the first study regarding the cutaneous findings of COVID‐19, reported varicella‐like lesions in one of 18 patients. Marzona et al 19 also identified varicella‐like eruption in 12 out of 22 patients with COVID‐19 and they concluded that this type of eruption may be a specific manifestation of COVID‐19. Casas Galvan et al 7 described small monomorphic vesicles located on the trunk in 9% of 375 patients with COVID‐19.…”
Section: Papulovesicular Eruptionsmentioning
confidence: 97%
“…5,6 Italian researchers described 22 patients with scattered or diffuse varicella-like vesiculopapular eruptions, representing the largest cohort of COVID-19 patients published thus far with similar cutaneous eruptions. 6 The authors concluded that these vesiculopapular eruptions were specifi c to COVID-19, stressing that no patient in their cohort had been exposed to new medications in the 15 days before eruption onset. Median latency time from COVID-19 systemic symptoms to the rash was 3 days, and the median duration of skin manifestations was 8 days.…”
Section: ■ Morbilliform Rashmentioning
confidence: 99%